Abstract
Nucleoside analogues are widely used for the treament of hematological malignancies and solid tumors. Their activity is based on the interference with cellular targets involved in the metabolism of physiological nucleosides and DNA synthesis. Unfortunately, various resistance mechanisms decrease the activity of these drugs, reducing their clinical efficacy. Here, we review different resistance mechanisms responsible for decreased in vitro and in vivo nucleoside analogue activity, and some of the strategies proposed to circumvent constitutive or acquired drug resistance.
Keywords: antimetabolites, drug resistance, neoplasms, nucleotidases
Current Drug Targets
Title: Drug Resistance to Cytotoxic Nucleoside Analogues
Volume: 4 Issue: 6
Author(s): L. Jordheim, C. M. Galmarini and C. Dumontet
Affiliation:
Keywords: antimetabolites, drug resistance, neoplasms, nucleotidases
Abstract: Nucleoside analogues are widely used for the treament of hematological malignancies and solid tumors. Their activity is based on the interference with cellular targets involved in the metabolism of physiological nucleosides and DNA synthesis. Unfortunately, various resistance mechanisms decrease the activity of these drugs, reducing their clinical efficacy. Here, we review different resistance mechanisms responsible for decreased in vitro and in vivo nucleoside analogue activity, and some of the strategies proposed to circumvent constitutive or acquired drug resistance.
Export Options
About this article
Cite this article as:
Jordheim L., Galmarini M. C. and Dumontet C., Drug Resistance to Cytotoxic Nucleoside Analogues, Current Drug Targets 2003; 4 (6) . https://dx.doi.org/10.2174/1389450033490957
DOI https://dx.doi.org/10.2174/1389450033490957 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progestins for Symptomatic Endometriosis: Results of Clinical Studies
Current Drug Therapy Immune Therapy in Pancreatic Cancer: Now and the Future?
Reviews on Recent Clinical Trials Sugar-Borate Esters – Potential Chemical Agents in Prostate Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Cancer Therapy Based on a Mechanism of Action for Controlling the Immune System and the Resulting Patent Portfolio
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery An Update of Radiolabeled Bombesin Analogs for Gastrin-Releasing Peptide Receptor Targeting
Current Pharmaceutical Design Beneficial and Adverse Effects of Molecularly Targeted Therapies for Acute Promyelocytic Leukemia in Central Nervous System
CNS & Neurological Disorders - Drug Targets Current Advances in Retroviral Gene Therapy
Current Gene Therapy Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia
Current Cancer Drug Targets Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design Detection of Predictive Markers for Therapeutic Stratification of Salivary Glands Tumors
Current Drug Targets Disorders of Protein Biogenesis and Stability
Protein & Peptide Letters ras Genes and Human Cancer: Different Implications and Different Roles
Current Genomics Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design TGF-β Signaling in Gastrointestinal Cancer Stem Cells
Current Cancer Therapy Reviews The Role of SHP-2 in Cell Signalling and Human Disease
Current Enzyme Inhibition Nuclear Factor Kappa B is a Promising Therapeutic Target in Inflammatory Lung Disease
Current Drug Targets Clinical Development of mTOR Inhibitors: A Focus on Lymphoma
Reviews on Recent Clinical Trials Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer
Current Medicinal Chemistry Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Current Cancer Drug Targets